Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics
Autolus Therapeutics plc - American Depositary Share (AUTL)
Today's Latest Price: $5.44 USD
Updated Mar 27 12:00am
Add AUTL to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
AUTL Stock Summary
- Autolus Therapeutics plc's stock had its IPO on June 22, 2018, making it an older stock than just 3.06% of US equities in our set.
- For AUTL, its debt to operating expenses ratio is greater than that reported by only 0.34% of US equities we're observing.
- With a price/sales ratio of 69.3, Autolus Therapeutics plc has a higher such ratio than 98.09% of stocks in our set.
- Stocks that are quantitatively similar to AUTL, based on their financial statements, market capitalization, and price volatility, are ARVN, BLUE, CLLS, TBPH, and ASMB.
- AUTL's SEC filings can be seen here. And to visit Autolus Therapeutics plc's official web site, go to www.autolus.com.
AUTL Stock Price Chart More Charts
AUTL Price/Volume Stats
| Current price | $5.44 | 52-week high | $32.84 |
| Prev. close | $5.62 | 52-week low | $3.00 |
| Day low | $4.57 | Volume | 81,600 |
| Day high | $5.73 | Avg. volume | 194,785 |
| 50-day MA | $8.66 | Dividend yield | N/A |
| 200-day MA | $12.19 | Market Cap | 218.39M |
Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio
Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.
Top Stories View All
Top 4 Home Improvement Stocks with Stimulus Checks on the Way
Rip Your Face Off Rally!
Best & Worst Performing Stock Industries for March 27, 2020
Best & Worst Performing Small Cap Stocks for March 27, 2020
Best & Worst Performing Mid Cap Stocks for March 27, 2020
View All Top Stories
Loading social stream, please wait...